AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
Ken Beers joins CRA's Life Sciences Practice as Vice President
CRA is proud to welcome Kenneth J. Beers as a vice president in the Life Sciences Practice. Mr. Beers supports biopharmaceutical clients across a range of...